Serilink Biotechnology Company Limited (“Serilink”) specializes in peptide/protein drug synthesis, modification, and bioconjugations using novel technologies (OPA LinkTech).
Its primary focus is on the development of antibody/peptide drug conjugates (ADCs, PDCs, collectively referred to as XDCs) and glycoconjugate vaccines. Serilink collaborates with partners to co-develop drugs, aiming at advancing them to the PCC or further to IND stage.
We develop structurally innovative and performance-enhanced conjugated drug candidate compounds,empowering pharmaceutical companies in need of transformation and innovation, and providing new drug molecules and platform development technologies.